PREVENTIVE STRATEGIES IN THE STAGES OF FORMATION AND COURSE OF BRONCHOPULMONARY DYSPLASIA
https://doi.org/10.15690/pf.v11i2.955
Abstract
Prevention of development of bronchopulmonary dysplasia (BPD) and possibility of preventing severe course of the disease are the first-priority areas of neonatal pulmonology. Use of modern medical technologies allows protecting a premature infant’s respiratory system from as early as antenatal period of development. Use of the newest neonatal resuscitation protocols may prevent development of BPD. International experience and clinical data gathered by the authors demonstrate that seasonal palivizumab immune prevention of severe course of a respiratory syncytial viral infection in children with BPD results in rarer cases of hospitalization, resuscitation measures and fatal outcomes. The article presents modern preventive strategies used in this category of patients.
About the Authors
I. V. Davydova
Scientific Center of Children’s Health, Moscow
Russian Federation
PhD, head of the department of new study technologies of children’s development peculiarities and outpatient health level monitoring at the research institute of preventive pediatrics and medical rehabilitation of the Scientific Center of Children’s Health
Russian Federation
PhD, head of the department of new study technologies of children’s development peculiarities and outpatient health level monitoring at the research institute of preventive pediatrics and medical rehabilitation of the Scientific Center of Children’s Health
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Pirogov Russian National Medical Research University, Moscow
Russian Federation
Russian Federation
G. V. Yatsyk
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
N. A. Mayanskiy
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
E. P. Zimina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. S. Ostrovskaya
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Baranov А. А., Namazova-Baranova L.S., Davydova I.V. Sovremennye podkhody k profilaktike, diagnostike i lecheniyu bronkholegochnoi displazii [Modern Approaches to Prevention, Diagnostics and Treatment of Bronchopulmonary Dysplasia]. Moscow, Pediatr, 2013. pp. 8-9.
2. Namazova-Baranova L.S., Davydova I.V., Turti T.V. Farmateka = Paramecia. 2013; 1: 51–55.
3. Baranov А.А., Albitskii V.Y. Smertnost' detskogo naseleniya Rossii (tendentsii, prichiny i puti snizheniya) [Pediatric mortality in Russia: tendencies, reasons and means of reducing]. Moscow, Union of Pediatricians of Russia, 2009. pp. 342-347.
4. Davydova I.V., Migali A.V., Akoev Yu.S. etc. Spravochnik pediatra = Pediatrician’s manual. 2011; 4: 33–39.
5. Liggins G. C., Howie R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50: 515–525.
6. Figueras-Aloy J., Serrano M. M., Rodriguez J. P. et al. Antenatal glucocorticoid treatment decreases mortality and chronic lung disease in survivors among 23-to 28-week gestational age preterm infants. Am. J. Perinatol. 2005; 22 (8): 441–448.
7. Antonov A.G., Borisevich O.A., Burkova A.S., Ionov O.V., Kryuchko D.S., Lenyushkina A.A., Ryndin A.Yu., Filippov O.S., Chumakova O.V., Terekhova Yu.E. Metodicheskoe pis'mo «Intensiv naya terapiya i printsipy vykhazhivaniya detei s ekstremal'no nizkoi i ochen' nizkoi massoi tela pri rozhdenii». Pod red. d.m.n., professora Baibarinoi E.N., d.m.n., professora Degtyareva D.N. [Methodological Letter “Intensive Therapy and Principles of Developmental Care of Infants with Extremely Low or Very Low Birth Weight”. Edited by PhD, Professor E.N. Baibarina and PhD, Professor D.N. Degtyarev]. Moscow, 2011. 72 p.
8. Kribs A. et al. Surfactant without Intubation in Preterm Infants with Respiratory Distress: First Multi-center Data. Сlin. Paеdiatr. 2010; 222: 13–17.
9. Singh N., Hawley K. L., Viswanathan K. Efficacy of Pocine Versus Bovine Surfactant for Preterm Newborns With Respiratory Distress Syndrome: Review and Meta-analysis. Pediatrics. 2001; 128: 1588–1595.
10. Engle W.A. Committee on Fetus and Newborn: Surfactant Replaycement Therapy for Respiratory Distress in the Preterm and Term Neonate. Pediatrics. 2008; 121: 419–432.
11. Volodin N.N., Baybarina E.N. Protokol vedeniya nedonoshennykh detei s gemodinamicheski znachimym funktsioniruyushchim arterial'nym protokom [Management Protocol for Premature Infants with Hemodynamically Significant Functioning Arterial Duct]. Moscow, 2010. 34 p.
12. Halliday H. L., Ehrenkranz R. A., Doyle L. W. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2009. CD001145.
13. Henderson-Smart D. J., Steer P. A. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews. 2010. CD000273.
14. Stewart A., Brion L. P. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001453.
15. Stewart A., Brion L. P., Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001817.
16. Tyson J. E., Wright L. L., Oh W. et al. Vitamin A supplementation for extremely-low-birth-weight infants. N. Engl. J. Med. 1999; 340: 1962–1968.
17. Merrill J. D., Ballard R. A., Cnaan A. et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr. Res. 2004; 56: 1–9.
18. Thomas W., Speer C. O. Bronchopulmonale Dysplasie Fruehgeborener Epidemiologie, Pathogenese und Therapie. Monatsschrift Kinderheilkd. 2005; 153: 211–219.
19. Laughon M., Bose C., Moya F., Aschner J. et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. Pediatrics. 2009; 123 (1): 89–96.
20. Ryndin A.Y., Antonov A.G. Patent RU 2416388 C1 «Sposob profilaktiki bronkholegochnoi displazii u novorozhdennykh s ochen' nizkoi i ekstremal'no nizkoi massoi tela pri rozhdenii». Byull. № 11 [Patent No. RU 2416388 C1 “Method of preventing bronchopulmonary dysplasia in neonates with very low or extremely low birth weight”. Bulletin. No. 11]. Moscow, 2011.
21. Northway W.H.Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronch opulmonary dysplasia. N. Engl. J. Med. 1967; 276: 357–368.
22. Simoes E. A. F. Respiratory syncytial virus infection. Lancet. 1999; 354 (9181): 847–852.
23. Ostrovskaya A.S., Davydova I.V., Lazareva A.V., Mayanskii N.A. Otsenka virusno-mikrobnogo peizazha nosoglotki u detei s bronkholegochnoi displaziei vne obostreniya zabolevaniya. [Evaluation of nasopharyngeal viromicrboial flora in children with non-acute bronchopulmonary dysplasia]. Materialy XVII Kongressa pediatrov Rossii s mezhdunarodnym uchastiem «Aktual'nye problemy pediatrii» (Proceedings of the XVII International Congress of Pediatricians of Russia “Relevant Issues of Pediatrics”). Moscow, 2014. p. 247.
24. Garenne M., Ronsmans C., Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q. 1992; 45 (2–3): 180–191.
25. Colin A. M., McEnvoy C., Castile R. Respiratory morbidity and lung function in preterm infants 32–36 weeks gestational age. Pediatrics. 2010. DOI: 10.1542/peds.2009. P. 1381.
26. Boyce T. G., Mellen B. G., Mitchel E. F. et al. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J. Pediatr. 2000; 137: 865–870.
27. Horn S. D., Smout R. J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J. Pediatr. 2003; 143: 133–141.
28. Baranov A.A., Davydova I.V., Namazova-Baranova L.S. etc. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9(6): 48–53.
29. Navas G. et al. Improved outcome of RSV infection in a highrisk hospitalized population of Canadian children. J. Pediatr.1992; 121: 348–354.
30. Davydova I.V., Yatsyk G.V., Tresorukova O.V. etc. Rossiiskii pediatricheskii zhurnal = Russian pediatric journal. 2008; 6: 10–13.
31. Glezen W. P., Taber L. H., Frank A. L. et al. Rick of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986; 140 (6): 543–546.
32. Everard M. Diagnosis, admission, discharge. Paediatr. Respir. Rev. 2009; 10 (Suppl. 1): 18–20.
33. Wellier R. C., Chechia P. A., Bauman J.H. et al. Fatality rates in published reports of RSV hospitalizations among highrisk and otherwise healthy children. Cu Med. Res. Opin. 2010; 29(9): 2175–2181.
34. Prince G. A., Jenson A. B., Hemming V. G. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus. Journal of Virology. 1986; 57: 721–728.
35. Sinagis (instruktsiya po primeneniyu) [Synagis: Application; the Abbott Laboratories].
36. Tatochenko V.K. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10(4): 30–37.
Review
For citations:
Davydova I.V., Namazova-Baranova L.S., Yatsyk G.V., Mayanskiy N.A., Zimina E.P., Ostrovskaya A.S. PREVENTIVE STRATEGIES IN THE STAGES OF FORMATION AND COURSE OF BRONCHOPULMONARY DYSPLASIA. Pediatric pharmacology. 2014;11(2):34-40. https://doi.org/10.15690/pf.v11i2.955
Views:
740
Email this article 